https://www.innovimmune.com/news daily 0.75 2025-04-29 https://www.innovimmune.com/news/hrdtg65kkpnnbz3 monthly 0.5 2025-04-29 https://www.innovimmune.com/news/2022/3/22/innovimmunes-proprietary-first-in-class-oral-inv-88-macrophage-migration-inhibitory-factor-mif-inhibitors-to-be-presented-at-the-2022-american-association-for-cancer-reserach-annual-meeting monthly 0.5 2025-04-29 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/563db786-ef0a-43c0-8297-49d43ba6242a/2022%2BAACR%2BINV-88%2BMIF%2Binhibitor%2BAffilitiations.png News - 2022.04.12. Innovimmune's first-in-class oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors to be presented at the 2022 American Association for Cancer Research Annual Meeting - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.innovimmune.com/news/2017/11/1/single-agent-antitumor-efficacy-of-a-novel-oral-inv-25-liver-x-receptor-lxr-agonist-in-a-checkpoint-refractory-mouse-b16-f10-melanoma-model-to-be-presented-at-the-2018-aad-meeting-in-s-dt4er monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2017/11/1/preclinical-poc-data-in-a-mouse-psoriasis-model-following-topical-treatment-with-small-molecule-inv-17-ror-gamma-inhibitor-to-be-presented-at-the-2017-eadv-annual-meeting-in-geneva-swi-sn6w4 monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/12/9/preclinical-psoriasis-data-of-innovimmunes-ror-gamma-inhibitor-to-be-presented-at-the-2017-aad-annual-meeting-in-orlando-fl monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/7/10/ror-gamma-inhibitortested-in-lupus-model monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/12/12/t785a1fax90t2t5yh2mtc356uliewc monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2017/11/8/innovimmune-awarded-nih-niaid-sbir-phase-ii-3-million-grant-for-development-of-its-oral-inv-88-mif-inhibitor-pipeline monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/7/10/rar-related-orphan-receptor-c-thymus-speci-c-isoform-rory2-roryt monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/7/10/autoimmune-disease-preclinical-findings monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/7/10/edrqh8yrcig4xd2e48kg3n5vv4t3py monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/7/10/innovimmune-structuring-immunotherapies monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2016/12/9/innovimmune-featured-in-xconomy monthly 0.5 2022-06-07 https://www.innovimmune.com/news/2017/11/8/innovimmune-awarded-nih-niaid-sbir-phase-i-300000-grant-for-the-development-of-its-proprietary-oral-inv-88-macrophage-migration-inhibitory-factor-mif-inhibitors-for-autoimmune-diseases monthly 0.5 2022-06-07 https://www.innovimmune.com/events daily 0.75 2022-06-07 https://www.innovimmune.com/events/2022/esmo-2022-paris-innovimmune-cancer-immunotherapy monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2022/bio-asia-2022-taiwan-innovimmune-partnering-licensing monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2022/bio-2022-san-diego monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2022/aacr-2022-new-orleans-annual-meeting monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2020/esmo-2020-madrid-spain-september-18-22-2020 monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2020/bio-asia-taiwan-2020 monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2020/6/5/aacr-2020-virtual-meeting-ii-june-22-24-2020 monthly 0.5 2022-06-07 https://www.innovimmune.com/events/biodigital2020 monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2020/5/5/covid-19-virtual-meeting-april-20-may-6-2020 monthly 0.5 2022-06-07 https://www.innovimmune.com/events/2022/3/22/new-york-lieutenant-governor-kathy-hochul-visits-innovimmune-1 monthly 0.5 2022-06-07 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/ecb20ed0-8f57-470f-9259-4ce0bcdcc60b/Lieutenant+Governor+Kathy+Hochul+at+Innovimmune.jpeg Events - 2015.12.16. New York Lieutenant Governor Kathy Hochul visits Innovimmune at the SUNY Downstate Advanced Biotechnology Park - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.innovimmune.com/home daily 1.0 2023-03-28 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/eb849e6a-0aa3-4161-8f4a-143eb71be9d9/Innovimmune+NCE+oral+medicine.jpeg Home - Our Mission We are building an innovative product pipeline of immunotherapies focused in the therapeutic areas of Cancer, Autoimmune Diseases and Chronic Inflammation. Our mission is to deliver orally administered medicines that make a real difference in quality of life for our patients. https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/e8737398-b9d2-46b3-ae81-47c75a9b7138/26286621446_16e0d0ec64_o.jpeg Home - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/8b74992b-d488-46a7-b8ac-0a7185ecce02/iStock_58564578_XXLARGE.jpg Home - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.innovimmune.com/platform daily 0.75 2022-06-08 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/97b7a695-6523-486b-8f80-1c110b67104d/Innovimmune+SBDD.jpg Platform - Enabling intractable disease-modifying proteins to be druggable targets Only a much smaller fraction of human proteins are currently drugged that are approved and available to treat patients. Important disease-causing proteins have traditionally been highlighted as intractable to small-molecule drugs. We discover new medicines by enabling intractable disease-modifying proteins to become druggable therapeutic targets using structure-guided drug design coupled with fragment-based drug design. We design synthetic compounds from detailed three-dimensional structural knowledge and active site characteristics of drug targets associated with cancer and inflammatory diseases. We integrate the disciplines of structural biology, X-ray crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals. https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/0a0d951c-ed58-44ca-8b0d-c1c4d8a993fe/Innovimmune+Platform.jpg Platform - Utilizing stringent Lipinski Rule-of-Five These discovery efforts allow our scientists to provide details of protein-ligand interactions and binding sites that inform chemical tractability, downstream biology, simultaneously generate clinical candidate selection compounds, and expansion of our broad intellectual property portfolio. Our proprietary compounds bind to pharmacophoric binding sites and inactivate disease-associated protein targets with unrivaled precision down to Angstrom level resolution. Utilizing Lipinski Rule-of-Five compliance, we achieve drug likeness, minimal toxicity and drug-drug-interactions, optimal bioavailability and enhanced efficacy. Our goal is to deliver highly efficacious and safe novel treatments to our patients suffering with Cancer, Autoimmune Diseases and Inflammation. https://www.innovimmune.com/oral-cancer-immunoncology-autoimmune-pipeline daily 0.75 2022-08-21 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/123c369e-290d-403b-89b5-f067be1fa9ae/220821_Pipeline.png Our Pipeline https://www.innovimmune.com/ror-gamma-rorg-inverse-agonist-autoimmune-disease-cancer daily 0.75 2023-11-27 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/34d2c762-953c-49c5-8807-f4c7a51f1860/ROR%2Bgamma%2Binverse%2Bagonist%2Bcancer%2Bautoimmune.png INV-17 Retinoic acid-related Orphan Receptor Gamma Inverse Agonist - Recent scientific findings have revealed an unexpected role for RORγ in regulating major oncogenic pathways contributing to stemness, aggressive behavior and tumor burden of cancer. Next-generation INV-17 RORγ inhibitors have been discovered with potent anti-tumor properties against various cancer models. https://www.innovimmune.com/aboutus daily 0.75 2023-08-19 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/8b74992b-d488-46a7-b8ac-0a7185ecce02/iStock_58564578_XXLARGE.jpg About - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.innovimmune.com/management daily 0.75 2022-05-30 https://www.innovimmune.com/advisory-board daily 0.75 2022-06-08 https://www.innovimmune.com/contact-us daily 0.75 2022-06-06 https://www.innovimmune.com/management/john-w-ellingboe daily 0.75 2022-05-30 https://www.innovimmune.com/mif-inhibitor-cancer-autoimmune-disease daily 0.75 2023-03-28 https://www.innovimmune.com/ror-gamma-rorg-agonist-cancer daily 0.75 2023-11-27 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/6b200517-7cb9-43e2-be28-acd916d62bec/ROR+gamma+agonist+cancer.jpg INV-71 Retinoic acid-related Orphan Receptor Gamma Agonist - Make it stand out Mechanism of Action of INV-71 RORγ Activation https://www.innovimmune.com/liver-x-receptor-lxr-agonist-cancer-alzheimer daily 0.75 2023-12-30 https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/ba95abe8-7fb8-4325-8a48-b69b943657d9/INV-25+LXR+Cancer.png https://images.squarespace-cdn.com/content/v1/6287d3fb94a6c965088dc766/5d57d6da-95a6-4556-95e2-8525c3f9a7ba/INV-25+LXR+Alzheimer%27s+Disease.png https://www.innovimmune.com/management/anderson-gaweco daily 0.75 2024-07-17 https://www.innovimmune.com/management/jefferson-w-tilley daily 0.75 2022-05-30 https://www.innovimmune.com/management/william-t-windsor daily 0.75 2023-08-19 https://www.innovimmune.com/vincent-chung-md daily 0.75 2022-06-08 https://www.innovimmune.com/christian-sebesta-md daily 0.75 2022-06-22